Drug Profile
Research programme: natural killer cell stimulants - Innate Pharma/Novo Nordisk
Alternative Names: IPH 22XX; IPH 24Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Innate Pharma; Novo Nordisk
- Developer Innate Pharma
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Europe (Parenteral)
- 25 Aug 2010 Preclinical development is ongoing for Inflammation in Europe